KRYS News and Press, Krystal Biotech Inc. From 09/09/21

Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech I...

PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virt...

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21 Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21 Our wholly-owned subsidiary Jeune Aesthetics, ...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Krystal Biotech (KRYS) announces updated results from the Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis ((ARCI)) associated with mutations in the TGM1 gene.The data showed that repeat doses of KB10...

-  New data include update from the fourth patient treated in the Phase 1/2 trial -  Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH, July 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech I...

For life sciences investors, the gene therapy market is one of the most interesting plays today. The US National Library of Medicine defines gene therapies as specialized treatments using genes for the prevention or treatment of disease. Gene therapies are designed to treat ...

Krystal Biotech (KRYS): Q1 GAAP EPS of -$0.74 misses by $0.16.Cash, cash equivalents and short-term investments totaled $403.4 million on March 31, 2021.Press Release For further details see: Krystal Biotech EPS misses by $0.16

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million PITTSBURGH, May 10, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (...

PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global bio...